title: Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.
abstract: Combination therapy with subcutaneous peginterferon alpha-2a (40KD) [Pegasys] plus oral ribavirin (Copegus) has been evaluated previously in patients with chronic hepatitis C and elevated ALT levels. A recent randomised, nonblind, multicentre trial examined the efficacy of this combination therapy in the treatment of patients with persistently 'normal' ALT levels. These trial results showed that combination therapy with peginterferon alpha-2a (40KD) plus ribavirin is effective in patients with chronic hepatitis C and persistently normal ALT levels. Overall, a sustained virological response occurred in over 50% of patients who received combination therapy for 48 weeks, albeit with a low daily dosage of ribavirin. The tolerability profile of combination therapy in patients with persistently normal ALT levels is similar to that seen in patients with elevated ALT levels. The decision as to whether or not treatment should be initiated in patients with chronic hepatitis C and persistently normal ALT levels should be made on an individual basis. If a decision is made to treat, combination therapy with peginterferon alpha-2a (40KD) plus ribavirin can be considered a first-line treatment option.
authors.affiliation: Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
authors.forename: Greg L
authors.initials: GL
authors.lastname: Plosker
mesh_terms: D000410:Alanine Transaminase / Q000378:metabolism; D000998:Antiviral Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000494:pharmacology*; D011788:Quality of Life; D011994:Recombinant Proteins; D012254:Ribavirin / Q000494:pharmacology*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000410:Alanine Transaminase; C100416:peginterferon alfa-2a
references.citation: Hepatology. 1998 Mar;27(3):868-72
references.pmid: 9500720
references.citation: Am J Gastroenterol. 2004 Sep;99(9):1706-7
references.pmid: 15330906
references.citation: Drugs. 2001;61(15):2263-88
references.pmid: 11772139
references.citation: Hepatology. 2004 Apr;39(4):1147-71
references.pmid: 15057920
references.citation: Ann Intern Med. 2004 Mar 2;140(5):346-55
references.pmid: 14996676
references.citation: Hepatology. 1997 Aug;26(2):473-7
references.pmid: 9252161
references.citation: J Hepatol. 2003 Apr;38(4):511-7
references.pmid: 12663245
references.citation: Gastroenterology. 2004 May;126(5):1409-15
references.pmid: 15131801
references.citation: Gastroenterology. 2004 Mar;126(3):703-14
references.pmid: 14988824
references.citation: BMJ. 2004 Apr 24;328(7446):983
references.pmid: 15028636
references.citation: Hepatology. 1992 Sep;16(3):649-54
references.pmid: 1505907
references.citation: J Med Virol. 2003 Jan;69(1):50-8
references.pmid: 12436477
references.citation: Br J Clin Pharmacol. 2000 May;49(5):417-21
references.pmid: 10792198
references.citation: NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46
references.pmid: 14768714
references.citation: Expert Opin Pharmacother. 2003 Apr;4(4):541-51
references.pmid: 12667117
references.citation: Hepatology. 2004 Dec;40(6):1442-9
references.pmid: 15565603
references.citation: Hepatology. 1997 Sep;26(3 Suppl 1):133S-136S
references.pmid: 9305678
references.citation: BMJ. 2001 Nov 17;323(7322):1141-2
references.pmid: 11711386
references.citation: Hepatology. 2002 Nov;36(5 Suppl 1):S179-84
references.pmid: 12407592
references.citation: N Engl J Med. 2001 Jul 5;345(1):41-52
references.pmid: 11439948
references.citation: J Hepatol. 1996 Nov;25(5):591-8
references.pmid: 8938532
references.citation: J Hepatol. 1999;31 Suppl 1:9-16
references.pmid: 10622554
references.citation: Rev Infect Dis. 1990 Nov-Dec;12(6):1139-46
references.pmid: 2267489
references.citation: J Immunol. 1998 Apr 1;160(7):3487-93
references.pmid: 9531310
references.citation: J Med Virol. 1993 Oct;41(2):99-102
references.pmid: 8283183
references.citation: Pharmacol Ther. 1979;6(1):123-46
references.pmid: 390559
references.citation: Gastroenterology. 2002 Oct;123(4):1070-83
references.pmid: 12360469
references.citation: Ann Intern Med. 2002 Jul 2;137(1):1-10
references.pmid: 12093239
references.citation: Drugs. 2003;63(7):701-30
references.pmid: 12656650
references.citation: Gastroenterology. 2004 Dec;127(6):1724-32
references.pmid: 15578510
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: J Gen Virol. 1998 Oct;79 ( Pt 10):2381-91
references.pmid: 9780043
references.citation: Ann Intern Med. 2002 Dec 17;137(12):961-4
references.pmid: 12484711
references.citation: J Hepatol. 1999 Mar;30(3):376-82
references.pmid: 10190717
references.citation: Hepatology. 2002 Oct;36(4 Pt 1):973-7
references.pmid: 12297846